Detalles de la búsqueda
1.
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study.
Int J Cancer
; 153(1): 141-152, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757197
2.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976398
3.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431518
4.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
5.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer
; 149(11): 1935-1943, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310714
6.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
7.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33154570
8.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982686
9.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575024
10.
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
BMC Cancer
; 16: 699, 2016 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-27582078
11.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940
12.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Gut
; 62(5): 751-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22773551
13.
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
Cancer Med
; 12(3): 2739-2751, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36017743
14.
Usage of Complementary and Alternative Methods, Lifestyle, and Psychological Variables in Cancer Care.
In Vivo
; 37(1): 106-114, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36593056
15.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Eur J Cancer
; 190: 112955, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37454537
16.
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
BMC Cancer
; 11: 367, 2011 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-21861888
17.
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
Eur J Cancer
; 137: 250-259, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32810748
18.
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).
Oncotarget
; 8(62): 105749-105760, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29285289
19.
Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
J Clin Oncol
; 23(33): 8389-95, 2005 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16293869
20.
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Clin Lung Cancer
; 8(2): 135-9, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17026815